NADAC acquisition cost data for COPAXONE 40 MG/ML SYRINGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
| 68546032512 | $473.36 | 2022-05-18 | Rx |
Generic: Glatiramer Acetate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $836.9M | 128,170 | 15,871 | $438.86 |
| 2020 | $713.6M | 107,923 | 12,092 | $439.83 |
| 2021 | $556.5M | 82,866 | 9,680 | $442.80 |
| 2022 | $456.6M | 67,063 | 7,923 | $450.11 |
| 2023 | $369.4M | 54,312 | 6,385 | $454.51 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $34.2M | 4,794 | 608 |
| California | $29.9M | 4,291 | 532 |
| Pennsylvania | $29.9M | 4,520 | 520 |
| Florida | $23.5M | 3,496 | 413 |
| Michigan | $19.0M | 2,874 | 345 |
| Texas | $18.0M | 2,625 | 327 |
| New Jersey | $17.3M | 2,286 | 294 |
| Massachusetts | $15.1M | 2,234 | 259 |
| Ohio | $12.4M | 1,845 | 215 |
| Illinois | $11.7M | 1,634 | 212 |
| Georgia | $11.0M | 1,607 | 197 |
| North Carolina | $8.3M | 1,277 | 151 |
| Washington | $8.3M | 1,218 | 149 |
| Wisconsin | $8.1M | 1,196 | 151 |
| Missouri | $7.2M | 1,010 | 133 |
| Indiana | $7.0M | 1,058 | 128 |
| Minnesota | $7.0M | 1,044 | 129 |
| Tennessee | $6.4M | 1,005 | 115 |
| Connecticut | $6.4M | 886 | 107 |
| Maryland | $6.3M | 870 | 113 |
| Kentucky | $5.7M | 926 | 107 |
| Virginia | $5.5M | 830 | 105 |
| Arizona | $5.2M | 736 | 92 |
| South Carolina | $4.8M | 757 | 83 |
| Colorado | $4.4M | 651 | 82 |
| Nebraska | $4.3M | 720 | 72 |
| Oklahoma | $4.0M | 591 | 65 |
| Alabama | $3.9M | 578 | 70 |
| Oregon | $3.8M | 600 | 69 |
| Louisiana | $3.5M | 544 | 63 |
| Montana | $3.3M | 540 | 53 |
| Arkansas | $3.1M | 486 | 50 |
| Kansas | $2.9M | 444 | 52 |
| Nevada | $2.9M | 417 | 46 |
| Utah | $2.8M | 396 | 55 |
| Iowa | $2.3M | 345 | 44 |
| New Hampshire | $2.3M | 333 | 40 |
| Idaho | $2.1M | 313 | 45 |
| Puerto Rico | $1.9M | 319 | 34 |
| Mississippi | $1.9M | 280 | 35 |
| West Virginia | $1.7M | 254 | 33 |
| South Dakota | $1.6M | 250 | 29 |
| Maine | $1.3M | 225 | 22 |
| North Dakota | $1.3M | 174 | 21 |
| Vermont | $1.1M | 148 | 18 |
| District of Columbia | $995.2K | 149 | 18 |
| New Mexico | $886.3K | 129 | 20 |
| Delaware | $866.0K | 107 | 15 |
| Alaska | $623.8K | 93 | N/A |
| Wyoming | $490.6K | 77 | N/A |
| Rhode Island | $480.8K | 72 | N/A |
| Hawaii | $196.5K | 32 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.